[1]陆 新,龙 瑾.中成药辅助治疗高血压病胰岛素抵抗临床应用规范化研究[J].医学信息,2024,37(13):70-79.[doi:10.3969/j.issn.1006-1959.2024.13.014]
 Study on the Standardization of Clinical Application of Chinese Patent Medicine in the Adjuvant Treatment of Insulin Resistance in Hypertension.Study on the Standardization of Clinical Application of Chinese Patent Medicine in the Adjuvant Treatment of Insulin Resistance in Hypertension[J].Journal of Medical Information,2024,37(13):70-79.[doi:10.3969/j.issn.1006-1959.2024.13.014]
点击复制

中成药辅助治疗高血压病胰岛素抵抗临床应用规范化研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年13期
页码:
70-79
栏目:
论著
出版日期:
2024-07-01

文章信息/Info

Title:
Study on the Standardization of Clinical Application of Chinese Patent Medicine in the Adjuvant Treatment of Insulin Resistance in Hypertension
文章编号:
1006-1959(2024)13-0070-10
作者:
陆 新龙 瑾
(广西国际壮医医院内科,广西 南宁 530001)
Author(s):
Study on the Standardization of Clinical Application of Chinese Patent Medicine in the Adjuvant Treatment of Insulin Resistance in Hypertension
(Department of Internal Medicine,Guangxi International Zhuang Hospital,Nanning 530001,Guangxi,China)
关键词:
高血压病胰岛素抵抗GRADE系统中成药规范化应用
Keywords:
HypertensionInsulin resistanceGRADE systemChinese patent medicineStandardized application
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2024.13.014
文献标志码:
A
摘要:
目的 构建中成药治疗高血压病胰岛素抵抗(IR)患者的临床问题。通过检索并系统评价临床研究证据,由此形成相应推荐意见,为中成药辅助治疗高血压病IR提供循证,并为下一步诊疗规范化应用提供依据。方法 检索中国知网数据库(CNKI)、维普数据库(VIP)、万方数据库(Wanfang Data)、美国国立医学图书馆(MEDLINE)、荷兰医学文摘数据库(EMBASE)、考克兰图书馆(The Cochrane Library)6个数据库,收集从建库至2022年12月31日有高血压病IR随机对照试验(RCT)原始文献。通过专家问卷调查法确定拟解决的问题,经解构运用PICO原则进行设置为关键、重要、次要及安全性结局指标。采用Meta方法对文献证据指标分析讨论,根据GRADE指南对证据质量评价分级,形成临床规范化应用推荐意见。结果 共纳入14篇文献系统评价,为11种中成药,包括44味中药,证据质量以中低质量为主,73个结局指标中,10个为中级质量,11个为低级质量,余为极低级质量。目前研究前证据显示,中成药辅助治疗高血压病IR可提高ISI、HDL-C,降低HOMA-IR、FINS、FPG、TC、TG(IB)、LDL-C。结论 依据中医辨证论治及证据分级,补肾益心片、防己黄芪胶囊为强推荐,血压平胶囊、加味二至丸、复方七芍降压片、降压定眩片、降压脉净冲剂、芪黄颗粒、针箭颗粒、血脂康胶囊、四泰片为弱推荐。
Abstract:
Objective To construct the clinical problems of Chinese patent medicine in the treatment of hypertension patients with insulin resistance (IR). By searching and systematically evaluating the clinical research evidence, the corresponding recommendations were formed, which provided evidence-based evidence for the adjuvant treatment of hypertension IR with Chinese patent medicine, and provided a basis for the standardized application of diagnosis and treatment in the next step.Methods Six databases, including CNKI, VIP, Wanfang Data, MEDLINE, EMBASE and The Cochrane Library, were searched to collect the original literature of randomized controlled trials (RCTs) on IR in hypertension from inception to December 31, 2022. Through the expert questionnaire survey method to determine the problem to be solved, the deconstruction of the use of PICO principles to set as the key, important, secondary and safety outcome of indicators. Meta-analysis was used to analyze and discuss the literature evidence indicators. According to the GRADE guidelines, the quality of evidence was evaluated and graded to form recommendations for clinical standardized application.Results A total of 14 systematic reviews were included, including 11 kinds of Chinese patent medicines, with 44 kinds of traditional Chinese medicines. The quality of evidence was mainly medium and low quality. Among the 73 outcome indicators, 10 were intermediate quality, 11 were low quality, and the rest were very low quality. The current evidence before the study showed that Chinese patent medicine adjuvant treatment of hypertension IR could increase ISI, HDL-C, reduce HOMA-IR, FINS, FPG, TC, TG (IB), LDL-C.Conclusion According to TCM syndrome differentiation and evidence classification, Bushen Yixin tablets and Fangji Huangqi capsules are strongly recommended, and Xueyapin gcapsules, Jiawei Erzhipills, Compound Qishao Jiangya tablets, Jiangya Dingxuan tablets, Jiangya Maijing granules, Qihuang granules, Zhenjian granules, Xuezhikang capsules and Sitai tablets are weakly recommended.

参考文献/References:

[1]马丽媛,王增武,樊静,等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志,2022,30(7):481-496.[2]毕思玲.基于临床科研一体化系统的胰岛素抵抗相关疾病的证型分布、用药规律和有效处方分子机理分析[D].济南:山东中医药大学,2022.[3]于昊伟,张晓宇,李国军,等.降压定眩片对原发性高血压病患者胰岛素抵抗及血清瘦素水平的影响[J].解放军医药杂志,2017,29(12):89-92.[4]陆新,云宇.调气通路法结合西药治疗原发性高血压病胰岛素抵抗的临床研究[J].湖南中医杂志,2021,37(10):1-4,11.[5]王亦菲,郭丽君,高风,等.20种常用中成药治疗高血压病的临床研究证据图分析[J].中国中药杂志,2022,47(18):5097-5105.[6]陆新,蒋嘉诚.高血压病伴胰岛素抵抗中医内治法及用药配伍特点文献分析[J].北京中医药,2019,38(6):577-580.[7]段小容,余振球,司晓云,等.对高血压防治指南的认识[J].中华高血压杂志,2022,30(9):818-823.[8]邓通,汪洋,黄笛,等.临床实践指南制订方法——GRADE方法理论篇[J].中国循证心血管医学杂志,2018,10(12):1441-1449.[9]王云云,邓通,黄桥,等.临床实践指南制订方法——GRADE在诊断试验系统评价中的应用[J].中国循证心血管医学杂志,2019,11(3):275-279.[10]李文晞,吴伟,黄衍寿,等.补肾益心片改善高血压病胰岛素抵抗30例临床观察[J].新中医,2002,34(7):34-35.[11]王芸素.补肾益心片改善高血压病患者胰岛素抵抗的临床研究[D].广州:广州中医药大学,2002.[12]李华芳.血压平胶囊治疗高血压病伴胰岛素抵杭的临床研究[D].长沙:湖南中医药大学,2009.[13]肖艳.防己黄芪胶囊调节高血压代谢异常的临床研究[D].广州:广州中医药大学,2002.[14]谭胜真,谭元生,刘鑫,等.复方七芍降压片治疗高血压病伴胰岛素抵抗[J].南华大学学报(医学版),2010,38(4):518-520,523.[15]魏晓娜.加味二至丸对高血压绝经后患者胰岛素抵抗影响的研究[D].广州:广州中医药大学,2016.[16]杨学青.降压脉净冲剂治疗高血压的临床研究[D].北京:北京中医药大学,2003.[17]张治祥,马宏秀.芪黄颗粒治疗气阴两虚血热肝热型高血压病60例[J].陕西中医,2008,29(6):663-665.[18]郭志华,袁肇凯,王东生.四泰片治疗高血压病胰岛素抵抗的临床研究[J].中成药,2004,26(2):162-164.[19]吴桂梅.血脂康胶囊对高血压糖调节受损患者胰岛素分泌及胰岛素敏感性的影响[D].南京:南京中医药大学,2013.[20]唐蜀华,蒋卫民,陈晓虎,等.针箭颗粒改善高血压病胰岛素抵抗的临床研究[J].中国中西医结合杂志,2000,20(7):511-514.[21]田颖,郭栋,彭伟,等.中成药治疗原发性高血压的系统评价再评价[J].中华高血压杂志,2022,30(10):964-975.[22]马晓聪,吴福佳,郑景辉,等.高血压胰岛素抵抗患者中医证素分布规律及相关影响因素的研究[J].右江民族医学院学报,2022,44(5):719-723,734.[23]国家心血管病医疗质量控制中心.《2021年中国心血管病医疗质量报告》概要[J].中国循环杂志,2021,36(11):1041-1064.[24]中华中医药学会,《胃复春治疗萎缩性胃炎癌前病变临床应用专家共识》项目组.胃复春治疗萎缩性胃炎癌前病变临床应用专家共识[J].中医杂志,2023,64(2):212-216.

相似文献/References:

[1]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(13):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[2]吕 宁,徐 昕,黄 永,等.公安民警皮肤软纤维瘤与代谢综合征危险因素相关性研究[J].医学信息,2018,31(10):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
 LV Ning,XU Xin,HUANG Yong,et al.Correlative Study on Skin Soft Fibroma and Risk Factors of Metabolic Syndrome in Public Security Police[J].Journal of Medical Information,2018,31(13):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
[3]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
 YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Journal of Medical Information,2018,31(13):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[4]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
 CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Journal of Medical Information,2022,35(13):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[5]何 丽.应激性高血糖与急性心肌梗死的机制研究[J].医学信息,2022,35(10):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
 HE Li.Mechanism of Stress Hyperglycemia and Acute Myocardial Infarction[J].Journal of Medical Information,2022,35(13):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
[6]赵连强,雍凯龙.天麻钩藤饮治疗高血压病的临床研究[J].医学信息,2018,31(22):158.[doi:10.3969/j.issn.1006-1959.2018.22.047]
 ZHAO Lian-qiang,YONG Kai-long.Clinical Study on Tianma Gouteng Decoction in Treating Hypertension[J].Journal of Medical Information,2018,31(13):158.[doi:10.3969/j.issn.1006-1959.2018.22.047]
[7]陈 丽,郝丽娟.多囊卵巢综合征患者腹型肥胖、高雄、胰岛素抵抗及脂代谢的相关性分析[J].医学信息,2022,35(12):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
 CHEN Li,HAO Li-juan.Correlation of Abdominal Obesity, Hyperandrogenism, Insulin Resistance and Lipid Metabolism in Patients with Polycystic Ovary Syndrome[J].Journal of Medical Information,2022,35(13):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
[8]谢小莉,李 燕,霍 敏,等.老年2型糖尿病患者轻度认知功能障碍与胰岛素抵抗、 白介素-6的相关性研究[J].医学信息,2019,32(15):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
 XIE Xiao-li,LI Yan,HUO Min,et al.Correlation between Mild Cognitive Impairment and Insulin Resistance and Interleukin-6 in Elderly Type 2 Diabetic Patients[J].Journal of Medical Information,2019,32(13):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
[9]王本泉,项本宏,邱 钧.胰岛素抵抗与甲状腺结节的关系研究进展[J].医学信息,2022,35(14):154.[doi:10.3969/j.issn.1006-1959.2022.14.040]
 WANG Ben-quan,XIANG Ben-hong,QIU Jun.Research Progress on the Relationship Between Insulin Resistance and Thyroid Nodules[J].Journal of Medical Information,2022,35(13):154.[doi:10.3969/j.issn.1006-1959.2022.14.040]
[10]刘柏基,熊波波.代谢综合征与良性前列腺增生合并下尿路症状的关系 及治疗研究[J].医学信息,2019,32(17):28.[doi:10.3969/j.issn.1006-1959.2019.17.010]
 LIU Bai-ji,XIONG Bo-bo.Relationship between Metabolic Syndrome and Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms and Treatment[J].Journal of Medical Information,2019,32(13):28.[doi:10.3969/j.issn.1006-1959.2019.17.010]

更新日期/Last Update: 1900-01-01